Week 10 2021
Stacy W. Gray, MD
Associate Clinical Professor
Stacy Gray, MD, AM is an Associate Clinical Professor with a primary appointment in the Division of Clinical Cancer Genomics in the Department of Population Sciences and a secondary appointment in the Department of Medical Oncology and Therapeutics Research at City of Hope. Dr. Gray received her MD from the University of Chicago Pritzker School of Medicine. She completed her residency in Internal Medicine and her fellowship in Hematology/Oncology at The University of Chicago Hospitals. While in fellowship, she obtained a Masters degree in Public Policy from the University of Chicago Harris School, followed by a post-doctoral research fellowship in cancer communication at the University of Pennsylvania. In 2008, she joined the faculty of the Dana-Farber Cancer Institute, the Brigham and Women's Hospital and Harvard Medical School where she worked as a medical oncologist and cancer outcomes researcher in the division of Population Sciences and the Lowe Center for Thoracic Oncology. Dr. Gray’s research focuses on understanding the medical and psychosocial outcomes related to the use of genomic technologies in cancer care. One of her goals is to understand the relationships between information dissemination on an individual and population level, and the adoption of personalized cancer technologies. She also studies the clinical implementation of cancer whole-exome sequencing (WES), the "actionability" of sequence data in different populations, the integration of genomic data into the electronic health record and the social and behavioral science methods that can be used to answer emerging questions in cancer dissemination and implementation research. Her overall goal is to gain a better understanding of how a variety of factors may be working to drive the use of new genomic technologies and design targeted interventions to improve the delivery of precision cancer medicine. Dr. Gray serves on the ASCO Cancer Research Committee, holds multiple leadership roles in an NIH research consortium research funding and has been supported by the National Human Genome Research Institute, The agency of Healthcare Research and Quality, The American Cancer Society, The American Society of Clinical Oncology, and The Robert Wood Johnson Foundation.
Thomas Slavin, MD, FACMG, DABMD
Vice President of Medical Affairs for Oncology
Dr. Slavin is Senior VicePresident of Medical Affairs for Oncology at Myriad Genetics. He is aphysician-scientist, triple-board-certified in clinical genetics, moleculardiagnostics and pediatrics. Most recently, he served as assistantprofessor in the departments of Medical Oncology & Therapeutics Researchand Population Sciences at City of Hope National Medical Center. Dr. Slavingraduated medical school with Alpha-Omega-Alpha-honors from the University ofSouth Florida. He completed his residency programs at Case Western Reserve inCleveland, Ohio; this training included a postdoctoral research year ingenetic epidemiology. He has also completed graduate course work towards aMasters degree in clinical research through the University of SouthernCalifornia. He is an active member of the American Association of CancerResearch, the American Society of Clinical Oncology (ASCO), the AmericanSociety of Human Genetics, the Collaborative Group of the Americas on InheritedColorectal Cancer, and is a fellow of the American College of Medical Geneticsand Genomics. He has served on National Comprehensive Cancer Network (NCCN)committees for both the genetics of and screening for colorectal cancer. He hasserved on three ClinGen expert working group committees for variantclassification of breast, gastrointestinal and ovarian cancer predispositiongenes. Focused on expanding genetics education for cancer care providers,Dr. Slavin has helped shape both ASCO University as well as City of Hope’shereditary genomics training program. He is a well-published researcher in thefield of medical genetics, including over 60 journal articles, multiple bookchapters, and numerous presentations at national and international medicalmeetings. He has been involved in many national cancer research grants, and wasa 2018 National Institutes of Health (NIH) K08-career development grantawardee.